First Time Loading...
A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 3.28 USD 2.5%
Updated: May 15, 2024

Aquestive Therapeutics Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aquestive Therapeutics Inc
Research & Development Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
A
Aquestive Therapeutics Inc
NASDAQ:AQST
Research & Development
-$15.5m
CAGR 3-Years
7%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Research & Development
-$15.2B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-6%
Bristol-Myers Squibb Co
NYSE:BMY
Research & Development
-$9.3B
CAGR 3-Years
1%
CAGR 5-Years
-12%
CAGR 10-Years
-10%
Pfizer Inc
NYSE:PFE
Research & Development
-$10.6B
CAGR 3-Years
-74%
CAGR 5-Years
N/A
CAGR 10-Years
-5%
Merck & Co Inc
NYSE:MRK
Research & Development
-$29.5B
CAGR 3-Years
-41%
CAGR 5-Years
-29%
CAGR 10-Years
-15%
Eli Lilly and Co
NYSE:LLY
Research & Development
-$9.9B
CAGR 3-Years
-16%
CAGR 5-Years
-14%
CAGR 10-Years
-6%

See Also

What is Aquestive Therapeutics Inc's Research & Development?
Research & Development
-15.5m USD

Based on the financial report for Mar 31, 2024, Aquestive Therapeutics Inc's Research & Development amounts to -15.5m USD.

What is Aquestive Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
7%

Over the last year, the Research & Development growth was 5%. The average annual Research & Development growth rates for Aquestive Therapeutics Inc have been 7% over the past three years , 7% over the past five years .